Pluripotent Stem Cells and Gene Therapy

Translating Gene Therapy to the Clinic: Techniques and Approaches

Volumn , Issue , 2015, Pages 11-26

  Angelos, Mathew G ^a   Kidwai, Fahad ^a,b   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cell therapy; Gene therapy; Genetic disease models; Induced pluripotent stem cells; Pharmaceutical testing; Pluripotency; Reprogramming

Indexed keywords

EID: 84944401311     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-800563-7.00002-6     Document Type: Chapter

References (134)

1. Gurdon J.B. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 1962, 10:622-640.
2. King T., Briggs R. Serial transplantation of embryonic nuclei. Cold Spring Harb Symp Quant Biol 1956, 21:271-290.
3. Wilmut I., Schnieke A.E., McWhire J., Kind A.J., Campbell K.H.S. Viable offspring derived from fetal and adult mammalian cells. Nature 1997, 385:810-813.
4. Li Z., et al. Cloned ferrets produced by somatic cell nuclear transfer. Dev Biol 2006, 293:439-448.
5. Wakayama S., et al. Equivalency of nuclear transfer-derived embryonic stem cells to those derived from fertilized mouse blastocysts. Stem Cells 2006, 24:2023-2033.
6. Baguisi A., et al. Production of goats by somatic cell nuclear transfer. Nat Biotechnol 1999, 17:456-461.
7. Meissner A., Jaenisch R. Mammalian nuclear transfer. Dev Dyn 2006, 235:2460-2469.
8. Evans M., Kaufman M. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
9. Smith A.G., et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 1988, 336:688-690.
10. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Dev Biol 1981, 78:7634-7638.
11. Niwa H., Ogawa K., Shimosato D., Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009, 460:118-122.
12. Williams R.L., et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988, 336:684-687.
13. Smith A.G., Hooper M.L. Buffalo rat liver cells produce a diffusible activity which inhibits the differentiation of murine embryonal carcinoma and embryonic stem cells. Dev Biol 1987, 121:1-9.
14. Thomson J.A. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
15. Xu C., et al. Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 2005, 23:315-323.
16. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
17. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
18. Yu J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
19. Plachta N., Bollenbach T., Pease S., Fraser S.E., Pantazis P. Oct4 kinetics predict cell lineage patterning in the early mammalian embryo. Nat Cell Biol 2011, 13:117-123.
20. Chambers I., Tomlinson S.R. The transcriptional foundation of pluripotency. Development 2009, 136:2311-2322.
21. Esch D., et al. A unique Oct4 interface is crucial for reprogramming to pluripotency. Nat Cell Biol 2013, 15:295-301.
22. Kim J.B., et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009, 136:411-419.
23. Kim J.B., Zaehres H., Araúzo-Bravo M.J., Schöler H.R. Generation of induced pluripotent stem cells from neural stem cells. Nat Protoc 2009, 4:1464-1470.
24. Ambrosetti D.C., et al. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Synergistic Activation of the Fibroblast Growth Factor 4 En. Mol Cell Biol 1997, 17:6321.
25. Masui S., et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 2007, 9:625-635.
26. Chambers I., et al. Nanog safeguards pluripotency and mediates germline development. Nature 2007, 450:1230-1234.
27. Hatano S.-Y., et al. Pluripotential competence of cells associated with Nanog activity. Mech Dev 2005, 122:67-79.
28. Ivanova N., et al. Dissecting self-renewal in stem cells with RNA interference. Nature 2006, 442:533-538.
29. Silva J., Chambers I., Pollard S., Smith A. Nanog promotes transfer of pluripotency after cell fusion. Nature 2006, 441:997-1001.
30. Miyanari Y., Torres-Padilla M.-E. Control of ground-state pluripotency by allelic regulation of Nanog. Nature 2012, 483:470-473.
31. Huangfu D., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
32. Kim J., Chu J., Shen X., Wang J., Orkin S.H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008, 132:1049-1061.
33. Knoepfler P.S., et al. Myc influences global chromatin structure. EMBO J 2006, 25:2723-2734.
34. Nakagawa M., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008, 26:101-106.
35. Judson R.L., Babiarz J.E., Venere M., Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009, 27:459-461.
36. Carey B.W., et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011, 9:588-598.
37. Stadtfeld M., et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-181.
38. Papapetrou E.P., et al. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci USA 2009, 106:12759-12764.
39. Rao M.S., Malik N. Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem 2012, 113:3061-3068.
40. Sommer C.A., et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009, 27:543-549.
41. Soldner F., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
42. Sommer C.A., et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010, 28:64-74.
43. Zwi-Dantsis L., et al. Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients. Eur Heart J 2013, 34:1575-1586.
44. Camnasio S., et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012, 46:41-51.
45. Somers A., et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010, 28:1728-1740.
46. Warren L., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
47. Tavernier G., et al. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. Biomaterials 2012, 33:412-417.
48. Lester S.N., Li K. Toll-like receptors in antiviral Innate Immunity. J Mol Biol 2013, 1-19. 10.1016/j.jmb.2013.11.024.
49. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
50. Drews K., et al. The cytotoxic and immunogenic hurdles associated with non-viral mRNA-mediated reprogramming of human fibroblasts. Biomaterials 2012, 33:4059-4068.
51. Merling R.K., et al. Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 2013, 121:e98-107.
52. Seki T., et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7:11-14.
53. Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B 2009, 85:348-362.
54. Ban H., et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011, 108:14234-14239.
55. Seki T., Yuasa S., Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc 2012, 7:718-728.
56. Chen I.-P., et al. Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia. Cell Reprogram 2013, 15:503-513.
57. Jin Z.-B., Okamoto S., Xiang P., Takahashi M. Integration-free induced pluripotent stem cells derived from retinitis pigmentosa patient for disease modeling. Stem Cells Transl Med 2012, 1:503-509.
58. Ono M., et al. Generation of induced pluripotent stem cells from human nasal epithelial cells using a Sendai virus vector. PLoS One 2012, 7:e42855.
59. Nishishita N., Takenaka C., Fusaki N., Kawamata S. Generation of human induced pluripotent stem cells from cord blood cells. J Stem Cells 2011, 6:101-108.
60. Marson A., et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008, 134:521-533.
61. Anokye-Danso F., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
62. Hu S., et al. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 2013, 31:259-268.
63. Lu D., et al. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLoS One 2012, 7:e40938.
64. Kaji K., et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
65. Woltjen K., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
66. Mali P., et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 2010, 28:713-720.
67. Hackett P.B., Largaespada D.A., Cooper L.J.N. A transposon and transposase system for human application. Mol Ther 2010, 18:674-683.
68. Muenthaisong S., et al. Generation of mouse induced pluripotent stem cells from different genetic backgrounds using Sleeping beauty transposon mediated gene transfer. Exp Cell Res 2012, 318:2482-2489.
69. Davis R.P., et al. Generation of induced pluripotent stem cells from human foetal fibroblasts using the Sleeping Beauty transposon gene delivery system. Differentiation 2013, 86:30-37.
70. Yu J., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
71. Chou B.-K., et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011, 21:518-529.
72. Hu K., et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011, 117:e109-19.
73. Hong H., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
74. Okita K., et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011, 8:409-412.
75. Okita K., et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 2013, 31:458-466.
76. Dietz W.M., et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther 2013, 21:1526-1535.
77. Jia F., et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010, 7:197-199.
78. Narsinh K.H., et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 2011, 6:78-88.
79. Obokata H., et al. Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature 2014, 505:641-647. Retracted.
80. Obokata H., et al. Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature 2014, 505:676-680. Retracted.
81. Simara P., Motl J., Kaufman D.S. Pluripotent stem cells and gene therapy. Transl Res 2013, 161(4):284-292. 10.1016/j.trsl.2013.01.001.
82. Dimos J.T., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
83. Chen H., et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 2014, 1-14. 10.1016/j.stem.2014.02.004.
84. Egawa N., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012, 4:145ra104.
85. Cai S., Chan Y., Shum D.K. Induced pluripotent stem cells and neurological disease models. Acta Physiol Sin 2014, 66:55-66.
86. Chang T., et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 2011, 29:2090-2093.
87. Nihei Y., et al. Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. J Biol Chem 2013, 288:8043-8052.
88. Cooper O., et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012, 4:141ra90.
89. Rakovic A., et al. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J Biol Chem 2013, 288:2223-2237.
90. Freed C.R., et al. Transplantation of embryonic dopamine neurons for Severe Parkinson's disease. N. Engl J Med 2001, 344:710-719.
91. Olanow C.W., et al. Expedited Publication A Double-blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson 's Disease. Ann Neurol 2003, 54:403-414.
92. Wernig M., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008, 105:5856-5861.
93. Hargus G., et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010, 107:15921-15926.
94. Lee G., et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012, 30:1244-1248.
95. Kaitin K.I. Obstacles and opportunities in new drug development. Clin Pharmacol Ther 2008, 83:210-212.
96. Sollano J.a, Kirsch J.M., Bala M.V., Chambers M.G., Harpole L.H. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Clin Pharmacol Ther 2008, 84:263-266.
97. Marchetto M.C.N., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
98. Xu Y., et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci USA 2010, 107:8129-8134.
99. Desbordes S.C., Studer L. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat Protoc 2013, 8:111-130.
100. Ben-David U., et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 2013, 12:167-179.
101. Desbordes S.C., et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2009, 2:602-612.
102. Kunisada Y., Tsubooka-Yamazoe N., Shoji M., Hosoya M. Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res 2012, 8:274-284.
103. Choi S.M., et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013, 57:2458-2468.
104. Xu X., Lei Y., Luo J., Wang J., Zhong Z. Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 2013, 10:213-227.
105. Tebas P., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl J Med 2014, 370:901-910.
106. Hanna J., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
107. Sebastiano V., et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011, 29:1717-1726.
108. Zou J., Mali P., Huang X., Dowey S.N., Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011, 118:4599-4608.
109. Sun N., Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 2013, 1-6. 10.1002/bit.25018.
110. High K.a Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2007, 466-472. 10.1182/asheducation-2007.1.466.
111. Hasbrouck N.C., High K.a AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 2008, 15:870-875.
112. Kren B.T., et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009, 119:2086-2099.
113. Scott D.W., Lozier J.N. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol 2012, 156:295-302.
114. Xu D., et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009, 106:808-813.
115. Yakura Y., et al. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system. Biochem. Biophys Res Commun 2013, 431:336-341.
116. Moldovan G.-L., D'Andrea A.D. How the fanconi anemia pathway guards the genome. Annu. Rev Genet 2009, 43:223-249.
117. Tolar J., et al. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther 2011, 19:1193-1198.
118. Tolar J., et al. Gene therapy for Fanconi anemia: one Step closer to the clinic. Hum Gene Ther 2012, 23(2):141-144.
119. Raya A., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009, 460:53-59.
120. Kaufman D.S. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009, 114:3513-3523.
121. Slukvin I.I. Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. Blood 2013, 122(23):4035-4056.
122. Soldner F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146:318-331.
123. An M.C., et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11:253-263.
124. Liu G.-H., et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 2011, 8:688-694.
125. Park I.-H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
126. Rashid S.T., et al. Technical Advance Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010, 120:3127-3136.
127. Garate Z., Davis B.R., Quintana-Bustamante O., Segovia J.C. New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum Gene Ther 2013, 24:571-583.
128. Tang C., Weissman I.L., Drukker M. Embryonic stem cell immunobiol. Methods Protoc. Methods Mol. Biol 2013, vol. 1029:17-31. Humana Press. N. Zavazava (Ed.).
129. Dressel R., et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J 2010, 24:2164-2177.
130. Tangvoranuntakul P., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003, 100:12045-12050.
131. Chung T.-L., et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells 2010, 28:1782-1793.
132. Kim K., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
133. Kamao H., et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports 2014, 2:205-218.
134. Kanemura H., et al. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One 2014, 9:e85336.